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A Letter to the Editor in response to: 
 
Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is Associated with Improved Early 
Outcomes of Childhood Tuberculous Meningitis. Pediatr Infect Dis J. 2016 
Jun;35(6):607–10. 
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To the editors: 
 
Tuberculous meningitis (TBM) is a devastating disease. With the currently available 
treatment regimens one in five children die and only a third of surviving children 
escape neurological sequelae.1 If there was any way of improving these outcomes 
significant mortality and morbidity would be averted. We were greatly interested, 
therefore, to read the study by Li et al regarding the use of linezolid in children with 
TBM in Beijing.2 
 
In many ways linezolid is an attractive therapeutic option given its good 
bioavailability, excellent CSF penetration and proven efficacy against M. 
tuberculosis. However, three major obstacles currently limit the use of linezolid in the 
treatment of pediatric TBM: efficacy, safety and current high cost. Until this report the 
only described use of linezolid in pediatric TBM had been in the successful treatment 
of a South African case of extensively drug-resistant TBM.3  
 
Caution is warranted in interpreting the efficacy of linezolid in the treatment of 
pediatric TBM from this report. The retrospective design, unrandomised nature of 
group allocations, and unblinded ascertainment of outcomes limit how much can be 
inferred. In terms of patient selection, children were given linezolid if they remained 
febrile after two weeks on conventional treatment and had no neurological 
improvement in that time. It is therefore unclear why over 50% of children in the 
control group had a fever clearance time of greater than 4 weeks. It would be useful 
for the authors to further clarify on what criteria the decision to use linezolid was 
made, and from what common reference point during therapy fever clearance time 
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comparisons were made. Persistent fever following initiation of anti-tuberculous 
therapy with confirmed drug susceptible strains of M. tuberculosis is a recognized, 
although unusual, clinical phenomenon.4  
 
It would also be important to know if the improved outcomes were due to linezolid 
improving the treatment of TBM generally, or if the advantage was the result of 
improved treatment in cases with drug resistance. Understanding this would allow 
clinicians to evaluate whether this drug should be reserved only for cases with drug 
resistance. It would therefore be interesting to know if there are any molecular or 
phenotypic drug resistance results available from either the 14 microbiologically 
confirmed TB cases, or from the TB source cases identified in 50 of the children.  
 
Regarding safety, the authors report no significant difference in adverse events (GI 
disturbance, hepatotoxicity, rash, peripheral neuropathy or thrombocytopenia) 
between the 36 children treated with linezolid and those who received standard 
treatment. However, it is unclear from the report how the children were evaluated for 
these and whether they may have experienced any other side effects (such as lactic 
acidosis, optic neuropathy, impaired renal function, raised amylase or 
hypoglycemia5).  
 
We commend the authors on reporting these cases and providing some much-
needed data where so little exists. We look forward to learning from their 
experiences in even more depth. In our opinion however, there is currently still 
insufficient evidence to warrant use of linezolid in paediatric TBM without information 
strongly suggestive of drug resistance.   
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